CTRI/2024/02/063092已完成Unknown
A Prescription Event Monitoring (PEM) Study to Evaluate the Effects of Adjuvant Therapy with ZincorespTM Tablets/ Syrup in Patients Having Recurrent Ear, Nose, Throat and Respiratory Disorders and Infections.
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 入组人数
- 500
- 试验地点
- 1
- 主要终点
- Improvement in symptoms of ear, nose, throat, and respiratory disorders and/or infections
研究概览
简要总结
All eligible subjects who meet the inclusion and exclusion criteria will be part of the study.
A detailed history will be obtained from the patients included in the study.
After baseline assessment, patients will be followed-up during the study period (week 1 ± 3 days, and week 2 ± 3 days, week 3 ± 3 days week 4 ± 3 days, week 8 ± 3 days, week 12 ± 3 days]
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 2.00 Year(s) 至 70.00 Year(s)（—）
- 性别
- All
入选标准
- •Age above 2 years of any gender.
- •Patients having recurrent episodes of any of the following:.
- •Fever associated with respiratory tract infections (RTI).
- •URTI (rhinitis (Acute/allergic/Nonallergic), Common cold, Sinusitis, pharyngitis, laryngitis, influenza).
- •Combined allergic rhinitis and asthma syndrome (CARAS).
- •Acute otitis media,.
- •titis media with effusion,.
- •Chronic suppurative otitis media
- •Patients and parents who are willing to give consent for their or the child’s participation respectively in study.
排除标准
- •Any evidence of malignancy.
- •History and clinical findings suggestive of metabolic diseases
- •History and clinical findings suggest chronic respiratory tract diseases including interstitial lung disease (ILD) and cystic fibrosis.
- •History of respiratory tract surgery.
- •Known diagnosis of congenital cardiac defects.
结局指标
主要结局
Improvement in symptoms of ear, nose, throat, and respiratory disorders and/or infections
时间窗: Baseline to Week 12
次要结局
- Total number of patients with at least one episode of upper respiratory tract infections((rhinitis, Common cold, Sinusitis, pharyngitis, laryngitis, otitis media, and influenza))
- Total number of patients with at least one episode of Acute otitis media, Otitis media with effusion, Chronic suppurative otitis media(Baseline to Week 12)
- Total number of patients not having any episode of respiratory tract infections (URTI) or exacerbations of existing conditions during the study period.(Baseline to Week 12)
- Total number of patients with Combined allergic rhinitis and asthma syndrome (CARAS).(Baseline to Week 12)
- Total number of patients experiencing at least one episode of fever during the study period.(Baseline to Week 12)
- Total number of patients requiring antimicrobial agents (antibiotics and antiviral drugs) during the study period.(Baseline to Week 12)
- Total number of patients requiring hospital admission, but not requiring supplemental oxygen during the study period.(Baseline to Week 12)
- Total number of patients requiring hospital admission, requiring supplemental oxygen during the study period.(Baseline to Week 12)
- Number of days of hospitalization required during the study period.(Baseline to Week 12)
- Total number of days of work lost by the patients due to illness during the study period.(Baseline to Week 12)
- Total number of episodes of infections lasting more than 7 days during the study period.(Baseline to Week 12)
- Time required to recover completely from infection during the study period.(Baseline to Week 12)
- Investigator global assessment for efficacy(Week 12)
- Investigator global assessment for safety and tolerability(Week 12)
- Patient global assessment for efficacy(Week 12)
- Patient global assessment for safety and tolerability(Week 12)
研究者
Dr Vaishali Thakare
D. Y. Patil Deemed to be University, School of Medicine, Navi Mumbai
研究点 (1)
Loading locations...
相似试验
尚未招募
Unknown
Prescription Event Monitoring Study of Emrok tab. and Emrok IV to evaluate the safety and efficacy in the patients who have bacterial infections.CTRI/2024/09/073689Wockhardt Ltd30,000
尚未招募
2 期
HDCD-092330 tablet for uncomplicated cystitisCTRI/2025/02/081387Himalaya Wellness Company120
尚未招募
不适用
Upadacitinib in Giant Cell Arteritis (GCA) With Active Large-vessel Involvement.NCT07354906Groupe français d'étude des Maladies Inflammatoires de loeil80
尚未招募
Unknown
A study to evaluate the efficacy and safety of CitraFit™ in subjects with cardiovascular risk factorsCTRI/2025/10/096023Ziran India80
尚未招募
Unknown
A Study to Assess How Well Karvol Plus Capsules Relieve Nasal Congestion and Related Symptoms in People with Common Cold, Allergies, or SinusitisCTRI/2025/07/091301Indoco Remedies Limited250